Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 6Active not recruiting 3Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Leukemia, Lymphocytic, Chronic, B-Cell 6Waldenstrom Macroglobulinemia 5Recurrence 5Lymphoma, Mantle-Cell 5Lymphoma, Follicular 4Lymphoma 2Leukemia 2B-cell Malignancies 2Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 282Rituximab 260Etoposide 161Filgrastim 155Vincristine 145Doxorubicin 134Prednisone 117Cytarabine 108Radiotherapy 102Peripheral Blood Stem Cell Transplantation 90Methotrexate 90fludarabine phosphate 87Melphalan 78Busulfan 71Dexamethasone 59Granulocyte Colony-Stimulating Factor 56Carmustine 53fludarabine 51Bortezomib 46Tacrolimus 44Mycophenolic Acid 41Antilymphocyte Serum 41Ifosfamide 40Leucovorin 39Gemcitabine 38Whole-Body Irradiation 36Cyclosporine 35Bendamustine Hydrochloride 34sargramostim 33Methylprednisolone 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lymphoma × zanubrutinib × Clear all
NCT02569476 2024-10-26

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

BeiGene

Phase 1 Completed
119 enrolled 34 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT02795182 2022-07-01

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

BeiGene

Phase 1 Completed
75 enrolled 17 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡